Operative management in patients with upper tract urothelial carcinoma in Iceland: a population-based study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Guðmundsson, Eiríkur Orri
Marteinsson, Valur Þór
Nikulásson, Sigfús Þór
MetadataShow full item record
CitationBjörnsson O, Jónsson E, Guðmundsson EO, Marteinsson VÞ, Nikulásson SÞ, Guðjónsson S. Operative management in patients with upper tract urothelial carcinoma in Iceland: a population-based study. Scand J Urol. 2021 Jun;55(3):197-202. doi: 10.1080/21681805.2021.1916073.
AbstractObjective: Radical nephroureterectomy is the standard treatment of organ-confined upper tract urothelial carcinoma (UTUC). The objective of this study was to investigate survival and bladder recurrence rate in Icelandic patients with UTUC who underwent radical nephroureterctomy (RNU) or other procedures with curative intent. Material and methods: All patients who were diagnosed with UTUC in Iceland from 2003 to 2016 and treated with curative intent were included in the study. Information on patients was obtained retrospectively from patients' medical records and from the Icelandic Cause of Death Registry. Results: Overall 63 patients underwent a procedure for UTUC with curative intent in Iceland during the study period. The median age was 71 years and the majority were male (65%). In 50 patients (79%), the tumor was a primary UTUC. The most common procedure was RNU (78%) and eight patients (13%) underwent a kidney-sparing procedure. No patient died within 90 d of surgery. Twenty-eight patients (44%) had pathological stage T2 or higher, whereas 35 patients (56%) had pathological stage T1 or lower. The median follow-up time was 98.8 months . During the follow-up time 25 patients (40%) were diagnosed with recurrence in the bladder. Five-year cancer-specific survival (CSS) was 67%. Conclusions: This population-based study shows that the oncologic outcome in Icelandic patients with UTUC is similar to what has been reported in other countries. Bladder recurrence rate is high and can hopefully be reduced by improvements in surgical and intravesical instillation treatment. Possibly more kidney-sparing surgeries could have been done during the study period; however, careful selection for those procedures is mandatory. Keywords: Upper tract urothelial carcinoma; bladder recurrence; nephroureterectomy; survival.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
- Authors: Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, Shariat SF, Rouprêt M
- Issue date: 2016 Dec
- Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
- Authors: Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA
- Issue date: 2012 Dec
- The characteristics of recurrent upper tract urothelial carcinoma after radical nephroureterectomy without bladder cuff excision.
- Authors: Kang M, Jeong CW, Kwak C, Kim HH, Ku JH
- Issue date: 2015 Mar
- Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool.
- Authors: Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF, UTUC Collaboration.
- Issue date: 2014 Mar
- The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
- Authors: Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Kosaka T, Mizuno R, Mikami S, Kikuchi E, Oya M
- Issue date: 2021 Mar